BIORA THERAPEUTICS INC (BIOR) Stock Fundamental Analysis
NASDAQ:BIOR - Nasdaq - US74319F3055 - Common Stock
Overall BIOR gets a fundamental rating of 2 out of 10. We evaluated BIOR against 572 industry peers in the Biotechnology industry. BIOR has a bad profitability rating. Also its financial health evaluation is rather negative. BIOR is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year BIOR has reported negative net income.
In the past year BIOR has reported a negative cash flow from operations.
In the past 5 years BIOR always reported negative net income.
In the past 5 years BIOR always reported negative operating cash flow.
1.2 Ratios
BIOR's Return On Assets of -217.44% is on the low side compared to the rest of the industry. BIOR is outperformed by 91.15% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -217.44% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-232.13%
ROA(5y)-209.25%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for BIOR so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
BIOR does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, BIOR has less shares outstanding
Compared to 5 years ago, BIOR has more shares outstanding
The debt/assets ratio for BIOR has been reduced compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of -116.59, we must say that BIOR is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of BIOR (-116.59) is worse than 98.05% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -116.59 |
ROIC/WACCN/A
WACC2.47%
2.3 Liquidity
BIOR has a Current Ratio of 0.05. This is a bad value and indicates that BIOR is not financially healthy enough and could expect problems in meeting its short term obligations.
The Current ratio of BIOR (0.05) is worse than 99.29% of its industry peers.
A Quick Ratio of 0.05 indicates that BIOR may have some problems paying its short term obligations.
With a Quick ratio value of 0.05, BIOR is not doing good in the industry: 99.29% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.05 | ||
| Quick Ratio | 0.05 |
3. Growth
3.1 Past
BIOR shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -22.72%.
The Revenue has grown by 8820.00% in the past year. This is a very strong growth!
BIOR shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -87.44% yearly.
EPS 1Y (TTM)-22.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%89.69%
Revenue 1Y (TTM)8820%
Revenue growth 3Y-72.86%
Revenue growth 5Y-87.44%
Sales Q2Q%N/A
3.2 Future
Based on estimates for the next years, BIOR will show a very strong growth in Earnings Per Share. The EPS will grow by 24.30% on average per year.
Based on estimates for the next years, BIOR will show a very strong growth in Revenue. The Revenue will grow by 933.87% on average per year.
EPS Next Y88.79%
EPS Next 2Y38.19%
EPS Next 3Y24.3%
EPS Next 5YN/A
Revenue Next Year39100%
Revenue Next 2Y3064.14%
Revenue Next 3Y933.87%
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
BIOR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BIOR. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
BIOR's earnings are expected to grow with 24.30% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.19%
EPS Next 3Y24.3%
5. Dividend
5.1 Amount
BIOR does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BIORA THERAPEUTICS INC
NASDAQ:BIOR (12/10/2024, 8:09:45 PM)
After market: 0.579 +0.02 (+3.45%)0.5597
-0.79 (-58.54%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners38.19%
Inst Owner Change0%
Ins Owners0.61%
Ins Owner Change-1.69%
Market Cap2.53M
Analysts82.86
Price Target34.68 (6096.18%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)55.44%
Min EPS beat(2)-28.34%
Max EPS beat(2)139.22%
EPS beat(4)2
Avg EPS beat(4)44.55%
Min EPS beat(4)-28.34%
Max EPS beat(4)139.22%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)248.72%
EPS NQ rev (1m)10.81%
EPS NQ rev (3m)-695.18%
EPS NY rev (1m)-2.43%
EPS NY rev (3m)-924.29%
Revenue NQ rev (1m)-54.55%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-23.46%
Revenue NY rev (3m)-23.46%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 2.84 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-10.84
EYN/A
EPS(NY)-7.46
Fwd EYN/A
FCF(TTM)-10.22
FCFYN/A
OCF(TTM)-10.16
OCFYN/A
SpS0.2
BVpS-23.59
TBVpS-24.93
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -217.44% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-232.13%
ROA(5y)-209.25%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.06
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 62.81% | ||
| Cap/Sales | 31.05% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.05 | ||
| Quick Ratio | 0.05 | ||
| Altman-Z | -116.59 |
F-Score4
WACC2.47%
ROIC/WACCN/A
Cap/Depr(3y)55.03%
Cap/Depr(5y)64.29%
Cap/Sales(3y)970%
Cap/Sales(5y)1076.52%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-22.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%89.69%
EPS Next Y88.79%
EPS Next 2Y38.19%
EPS Next 3Y24.3%
EPS Next 5YN/A
Revenue 1Y (TTM)8820%
Revenue growth 3Y-72.86%
Revenue growth 5Y-87.44%
Sales Q2Q%N/A
Revenue Next Year39100%
Revenue Next 2Y3064.14%
Revenue Next 3Y933.87%
Revenue Next 5YN/A
EBIT growth 1Y9.91%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year0.32%
EBIT Next 3Y-5.74%
EBIT Next 5YN/A
FCF growth 1Y50.94%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y50.85%
OCF growth 3YN/A
OCF growth 5YN/A